Recombinant HEPATITIS B Vaccine / Bio Farma Indonesia - LARVOL DELTA

Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III) (clinicaltrials.gov) - P3 | N=540 | Not yet recruiting | Sponsor: PT Bio Farma | Trial completion date: Aug 2024 ➔ May 2026 | Trial primary completion date: Jul 2024 ➔ May 2026

Trial completion date • Trial primary completion date • Hepatitis B • Infectious Disease • Inflammation

Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma) (clinicaltrials.gov) - P3 | N=0 | Withdrawn | Sponsor: PT Bio Farma | N=220 ➔ 0 | Trial completion date: Jul 2025 ➔ Dec 2026 | Not yet recruiting ➔ Withdrawn | Trial primary completion date: Apr 2025 ➔ Dec 2026

Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Hepatitis B • Infectious Disease • Inflammation • Influenza • Pertussis • Respiratory Diseases • Tetanus

Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma) (clinicaltrials.gov) - P3 | N=220 | Not yet recruiting | Sponsor: PT Bio Farma | Trial completion date: Feb 2023 ➔ Jul 2025 | Trial primary completion date: Dec 2022 ➔ Apr 2025

Trial completion date • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Influenza • Pertussis • Respiratory Diseases • Tetanus

Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III) (clinicaltrials.gov) - P3 | N=540 | Not yet recruiting | Sponsor: PT Bio Farma | Trial completion date: Dec 2022 ➔ Aug 2024 | Trial primary completion date: Nov 2022 ➔ Jul 2024

Trial completion date • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III) (clinicaltrials.gov) - P3 | N=540 | Not yet recruiting | Sponsor: PT Bio Farma

New P3 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma) (clinicaltrials.gov) - P3 | N=220 | Not yet recruiting | Sponsor: PT Bio Farma

New P3 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Pertussis • Respiratory Diseases • Tetanus